Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib vs Imatinib in Newly Diagnosed CP-CML
NCT02204644Phase 3Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Flumatinib in chronic myeloid leukemia (CML), sponsored by Hansoh Pharmaceutical Group. Started Jun 2014; status: completed.
02
Drugs
Flumatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02204644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204644.